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1. 
METHOD AND PROCESS FOR THE 
PRODUCTION OF MULTI-COATED 
RECOGNITIVE AND RELEASING SYSTEMS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Appli 
cation Ser. No. 60/894,451, filed Mar. 12, 2007, and is a 
continuation-in-part application of U.S. patent application 
Ser. No. 12/047.309, filed Mar. 12, 2008, the entire contents 
of which are incorporated herein by reference. 
TECHNICAL FIELD OF THE INVENTION 
The present invention relates in general to the field of the 
controlled release of agents, and more particularly, to novel 
compositions and methods for making controlled release con 
figurational biomimetic imprinting networks. 
STATEMENT OF FEDERALLY FUNDED 
RESEARCH 
None. 
BACKGROUND OF THE INVENTION 
Without limiting the scope of the invention, its background 
is described in connection with the recognition and controlled 
release of active agents from polymers. 
This invention relates generally to the field of microencap 
sulation, and, more particularly, to the development of micro 
particles and nanoparticles with multiple recognitive layers. 
In general, microencapsulation is achieved with fluidized bed 
processes. The fluidized bed coating process is a widely used 
technique for large particle size. Small particles coated in a 
fluidized bed tend to agglomerate and adhere to the wall of the 
bed due to the electrostatic charge and capillary forces result 
ing from the remaining solvent. 
Despite improvements in the range of particle sizes, other 
limitations exist in optimizing microcapsules to be applied in 
a variety of applications; in particular, the loading and deliv 
ery of therapeutic agents. It is therefore a need to optimize the 
particle coating process for the formation and drug delivery 
vehicles. It is a further need to have optimization to the 
Wurster process to form multiple-layers for increased func 
tionality, especially as drug delivery systems with multiple 
recognitive layers. 
SUMMARY OF THE INVENTION 
The needs of the invention set forth above as well as further 
and other needs and advantages of the present invention are 
achieved by the embodiments of the invention described 
herein below. 
In one embodiment, the present invention comprises a 
tablet polymer comprising two or more layers, wherein each 
of the two or more layers comprises at least one active agent 
and at least one molecular recognition polymer, wherein the 
two or more layers are compressed into a single tablet. In one 
aspect, the polymer comprises microparticles and may also 
include at least one of an adhesive, a binder, an inactive matrix 
or an excipient. In one aspect, the polymer is at least one of 
biocompatible, biodegradable, swellable, water-soluble, or 
porous. In another aspect, the recognitive portion of the layer 
is disrupted due to: osmosis upon the presence and binding of 













solubility of the polymeric network leading to polymer dis 
Solution; local temperature changes leading to expansion of 
the polymeric network and combinations thereof. In another 
aspect, the active agent is loaded into two or more layers, e.g., 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 
layers. In another aspect, the active agent is selected from 
pharmaceuticals, medical agents, food components, deter 
gents, bleaches, fabric softeners, fragrances, cosmetic prod 
ucts, air fresheners, room deodorant devices, perfumed Sub 
strates, perfumed plastics and pet collars. In one aspect, the 
polymer is selected from Poly(allylamine), Acrylic acid, 
Acrylamide, (Diethylamino)ethyl methacrylate, (Ethylami 
no)methacrylate, Methacrylic acid, methylmethacrylate, Tri 
azacyclononane-copper(II) complex, 2-(methacryloyXloxy) 
ethyl phosphate, methacrylamide, 2-(trifluoromethyl)acrylic 
acid, 3-aminophenylboronic acid, poly(allylamine), o-ph 
thalic dialdehyde, oleyl phenyl hydrogen phosphate, 4-vi 
nylpyridine, vinylimidazole, 2-acryloilamido-2,2'-methop 
ropane Sulfonic acid, Silica, organic silanes, N-(4-vinyl)- 
benzyl iminodiacetic acid, Ni(II)-nitrilotriacetic acid, 
N-acryloyl-alanine, ethylene glycol dimethacrylate, pen 
taerythritol triacrylate, pentaerythritol tetraacrylate, trim 
ethylolpropane trimethacrylate, vinyl triethoxysilane, vinyl 
trimethoxysilane, toluene 2,4-diisocyanate, epichlorohydrin, 
triglycerolate diacrylate, polystyrene Surface, Propylene gly 
col dimethacrylate, poly(ethylene glycol) in dimethacrylate, 
methacrylate derived silica, acrylonitrile, N,N'-dimethy 
lacrylamide, poly(ethylene glycol)diacrylate. The tablet may 
further comprise a coating. In one aspect, the tablet is a 
sphere, film, planar, semi-spherical, cylinder, rod, hemi 
spheres, conical, hemi-cylinders, bi-layer and combination 
thereof. 
Another embodiment of the present invention is a compo 
sition that comprises a tablet polymer comprising two or more 
layers, wherein each of the two or more layers comprises at 
least one active agent and at least one molecular recognition 
polymer, wherein the two or more layers are compressed into 
a single tablet. 
Yet another aspect of the present invention is a method of 
making a recognitive release system with limited Swelling 
upon exposure to solvent alone comprising: selecting one or 
more molecules for imprinting and one or more active agent; 
forming two or more polymeric recognitive network layers 
about the one or more molecules and the active agent, remov 
ing the molecule from the first and a second polymeric rec 
ognitive network; and compressing the two or more layers 
into a tablet. In one aspect, the method further comprised the 
step of coating the tablet. In another aspect, the two or more 
layers are formed about a core. In yet another aspect, the two 
or more layers are coated into multiple layers. In one aspect, 
the tablet is formed into a sphere, film, planar, semi-spherical, 
cylinder, rod, hemispheres, conical, hemi-cylinders and com 
bination thereof. In one aspect, the polymeric recognitive 
network is at least partially porous. In one aspect, the polymer 
comprises microparticles. In one aspect, the layers further 
comprise at least one of an adhesive, a binder, an inactive 
matrix or an excipient. In one aspect, the polymer is at least 
one of biocompatible, biodegradable, swellable, water 
soluble, or porous. In one aspect, the composition comprises 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 
layers. 
Examples of active agents for use with the present inven 
tion include pharmaceutical and medical applications, food 
components, detergents, bleaches, fabric softeners, fra 
grances, cosmetic products, air fresheners, room deodorant 
devices, perfumed Substrates, perfumed plastics and pet col 
lars. Other actives include food and cosmetic applications 
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that use hydrocolloids as imprinting carriers for polymers of 
high molecular weight, wherein the hydrocolloids are 
extracted from plants, seaweeds oranimal collagen, produced 
by microbial synthesis, and comprise polysaccharides, pro 
teins and combinations thereof. The molecule-imprinted net 
work may be a carbohydrate polymer of glycosidic type 
mono-Sugar repeative units, galactomannans, pectins, algi 
nates, carrageenans and Xanthan gum that are linear or 
branched, neutral oranionic and combinations thereof. Other 
examples include household products selected from laundry 
care; paper products; specialty cleaners (chlorinated cleaners, 
scouring pads, effervescent toilet bowl cleaner powders); air 
fresheners and combinations thereof. Further examples 
include personal care products selected from hair care (sham 
poos, hair mousses, styling agents); skin care (body lotions, 
Vitamin e, aloe Vera); bath products (moisture-triggered 
release products); body powders; toilet soap (milled or 
poured, ionic strength-triggered release) and combinations 
thereof. Also, cosmetics and treatment products selected from 
lipstick, eye-liner, foundation; base; blush; mascara; eye 
shadow; lip liner; facial powder, consealer, facial cream; 
make-up remover, mascara remover, make-up; skin treat 
ments and may even include one or more fragrances or car 
riers therefore that include cologne; perfume; sampling; anti 
perspirant; deodorant; anti-dandruff shampoos, athlete foot 
products and combinations thereof. Other actives include a 
Surfactant, a bleaching agent, a corrosion inhibitor, a Sudsing 
modifier, a fluorescent whitening agent, one or more 
enzymes, an anti redeposition agent, a color, a fragrance, one 
or more additives and combinations thereof. 
The present invention also include the release of active 
agent upon exposure to the cognate molecule or moiety that 
ultimately causes release upon a loss of structural integrity 
caused by, e.g., changes in solubility, pressure, a pH shift, a 
change in temperature, a temperature increase, enzymatic 
breakdown, diffusion and combinations thereof. The skilled 
artisan will also be able to be formed integrally or as a coating 
for controlled release or one or more layers of the active, the 
recognitive polymer or both. Furthermore, the polymeric rec 
ognitive network may beformed into one or more layers, each 
of which recognizes a different molecule, a different active or 
inert agent or both. The polymeric recognitive network is 
formed into a sphere, film, planar, semi-spherical, cylinder, 
rod, hemispheres, conical, hemi-cylinders and combination 
thereof and may also be at least partially porous. The poly 
meric recognitive network also may be formed into one or 
more layers, each of which recognizes a different molecule, 
and where a different active or inert agent may be contained 
between polymeric layers. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the features and 
advantages of the present invention, reference is now made to 
the detailed description of the invention along with the 
accompanying figures and in which: 
FIG. 1. Multilayer tablets with 9 layers from the first 
recipe. The thickness is approximately 3 mm and diameter is 
6.33 mm. 
FIG. 2. A 9-layer tablet: 5 recognitive layers with 4 bovine 
serum albumin layers in between. Note the distinct, lighter 
color where the BSA layers are and the different noticeable 
particles. 
FIGS. 3a and 3b. FIG. 3a is a 7-layer tablet made from 5 
wt % cellulose and 20 wt % PNVP; the thickness was approx. 
1.5 mm. FIG. 3b is a single-layer tablet from the same mix 













FIGS. 4a and 4b. FIG. 4a shows how a single-layer tablet 
in DI water cracked and crumbled to bottom after 20 min. 
Notice how a big part is still floating on top while part that 
cracked off is lying on bottom. FIG. 4b shows how a single 
layer tablet in 100 mg/dL D-glucose solution cracked after 60 
minutes. 
FIGS.5a and 5b. FIG.5a shows the single-layer tablet after 
18 hours in DI water. FIG. 5b shows the single-layer tablet 
after 18 hours in 100 mg/dL D-glucose and DI water. 
FIGS. 6a and 6b. These photos show the swelling of a 
9-layer tablet placed in 100 mg/dL glucose solution. This 
Swelling along the outside was observed starting at 6 min. 
FIGS. 7a and 7b. These photos show apiece that felloff the 
top of a 9-layer tablet placed in 100 mg/dL glucose solution 
after 13 minutes 
FIGS. 8a and 8b. These photos show the 9-layer tablet 
placed in 100 mg/dL glucose solution after several hours 
(FIG. 8a) and 20 hours (FIG. 8b). 
FIG. 9. A diagram indicating the several layers of an ideal 
multilaminate system. 
FIG. 10 is a graph that shows the release of bovine serum 
albumin from glucose recognitive, multilayered systems. 
DETAILED DESCRIPTION OF THE INVENTION 
While the making and using of various embodiments of the 
present invention are discussed in detail below, it should be 
appreciated that the present invention provides many appli 
cable inventive concepts that can be embodied in a wide 
variety of specific contexts. The specific embodiments dis 
cussed herein are merely illustrative of specific ways to make 
and use the invention and do not delimit the scope of the 
invention. 
To facilitate the understanding of this invention, a number 
of terms are defined below. Terms defined herein have mean 
ings as commonly understood by a person of ordinary skill in 
the areas relevant to the present invention. Terms such as “a”, 
“an and “the are not intended to refer to only a singular 
entity, but include the general class of which a specific 
example may be used for illustration. The terminology herein 
is used to describe specific embodiments of the invention, but 
their usage does not delimit the invention, except as outlined 
in the claims. 
As used herein, the term “active agent(s). “active ingredi 
ent(s).” “pharmaceutical ingredient(s), and “bioactive 
agent(s) are defined as drugs and/or pharmaceutically active 
ingredients. The present invention may be used to encapsu 
late, attach, bind or otherwise be used to affect the storage, 
stability, longevity and/or release of any of the following 
drugs as the pharmaceutically active agent in a composition. 
One or more of the following bioactive agents may be com 
bined with one or more carriers and the present invention 
(which may itself be the carrier): 
Analgesic anti-inflammatory agents such as, acetami 
nophen, aspirin, salicylic acid, methyl salicylate, choline Sali 
cylate, glycol salicylate, 1-menthol, camphor, mefenamic 
acid, fluiphenamic acid, indomethacin, diclofenac, alclofenac, 
ibuprofen, ketoprofen, naproxene, pranoprofen, fenoprofen, 
Sulindac, fenbufen, clidanac, flurbiprofen, indoprofen, pro 
tizidic acid, fentiazac, tolmetin, tiaprofenic acid, bendazac, 
bufexamac, piroxicam, phenylbutaZone, oxyphenbutaZone, 
clofeZone, pentazocine, mepirizole, and the like. 
Drugs having an action on the central nervous system, for 
example sedatives, hypnotics, antianxiety agents, analgesics 
and anesthetics, such as, chloral, buprenorphine, naloxone, 
haloperidol, fluphenazine, pentobarbital, phenobarbital, 
secobarbital, amobarbital, cyclobarbital, codeine, lidocaine, 
US 8,771,713 B2 
5 
tetracaine, dyclonine, dibucaine, cocaine, procaine, mepiv 
acaine, bupivacaine, etidocaine, prilocaine, benzocaine, fen 
tanyl, nicotine, and the like. Local anesthetics Such as, ben 
Zocaine, procaine, dibucaine, lidocaine, and the like. 
Antihistaminics or antiallergic agents such as, diphenhy 
dramine, dimenhydrinate, perphenazine, triprolidine, pyril 
amine, chlorcyclizine, promethazine, carbinoxamine, tripe 
lennamine, brompheniramine, hydroxy Zine, cyclizine, 
meclizine, clorprenaline, terfenadine, chlorpheniramine, and 
the like. Anti-allergenics such as, antazoline, methapyrilene, 
chlorpheniramine, pyrilamine, pheniramine, and the like. 
Decongestants such as, phenylephrine, ephedrine, naphazo 
line, tetrahydrozoline, and the like. 
Antipyretics such as, aspirin, Salicylamide, non-steroidal 
anti-inflammatory agents, and the like. Antimigrane agents 
Such as, dihydroergotamine, pizotyline, and the like. 
Acetonide anti-inflammatory agents, such as hydrocortisone, 
cortisone, dexamethasone, fluocinolone, triamcinolone, 
medrysone, prednisolone, flurandrenolide, prednisone, halci 
nonide, methylprednisolone, fludrocortisone, corticosterone, 
paramethasone, betamethasone, ibuprophen, naproxen, feno 
profen, fenbufen, flurbiprofen, indoprofen, ketoprofen, 
Suprofen, indomethacin, piroxicam, aspirin, salicylic acid, 
diflunisal, methyl salicylate, phenylbutaZone, Sulindac, mefe 
namic acid, meclofenamate Sodium, tolmetin, and the like. 
Muscle relaxants such as, tolperisone, baclofen, dantrolene 
Sodium, cyclobenzaprine. 
Steroids Such as, androgenic steriods, such as, testosterone, 
methyltestosterone, fluoxymesterone, estrogens such as, con 
jugated estrogens, esterified estrogens, estropipate, 17-B 
estradiol, 17-B estradiol Valerate, equilin, mestranol, estrone, 
estriol, 17B ethinyl estradiol, diethylstilbestrol, progesta 
tional agents, such as, progesterone, 19-norprogesterone, 
norethindrone, norethindrone acetate, melengestrol, chlor 
madinone, ethisterone, medroxyprogesterone acetate, 
hydroxyprogesterone caproate, ethynodiol diacetate, nor 
ethynodrel, 17-O. hydroxyprogesterone, dydrogesterone, 
dimethisterone, ethinylestrenol, norgestrel, demegestone, 
promegestone, megestrol acetate, and the like. 
Respiratory agents such as, theophilline and B2-adrenergic 
agonists, such as, albuterol, terbutaline, metaproterenol, rito 
drine, carbuterol, fenoterol, quinterenol, rimiterol, Solmefa 
mol, Soterenol, tetroquinol, and the like. Sympathomimetics 
Such as, dopamine, norepinephrine, phenylpropanolamine, 
phenylephrine, pseudoephedrine, amphetamine, propyl 
hexedrine, arecoline, and the like. 
Antimicrobial agents including antibacterial agents, anti 
fungal agents, antimycotic agents and antiviral agents; tetra 
cyclines such as, oxytetracycline, penicillins, such as, ampi 
cillin, cephalosporins such as, cefalotin, aminoglycosides, 
Such as, kanamycin, macrollides such as, erythromycin, 
chloramphenicol, iodides, nitrofrantoin, nystatin, amphoteri 
cin, fradiomycin, Sulfonamides, purrolnitrin, clotrimazole, 
miconazole chloramphenicol, Sulfacetamide, SulfamethaZ 
ine, Sulfadiazine, Sulfamerazine, Sulfamethizole and Sulfisox 
azole; antivirals, including idoxuridine, clarithromycin; and 
other anti-infectives including nitrofuraZone, and the like. 
Antihypertensive agents such as, clonidine, C.-methyldopa, 
reserpine, Syrosingopine, rescinnamine, cinnarizine, hydra 
Zine, prazosin, and the like. Antihypertensive diuretics Such 
as, chlorothiazide, hydrochlorothrazide, bendoflumethazide, 
trichlormethiazide, furosemide, tripamide, methylclothiaz 
ide, penfluzide, hydrothiazide, Spironolactone, metolaZone, 
and the like. Cardiotonics such as, digitalis, ubidecarenone, 
dopamine, and the like. Coronary vasodilators such as, 
organic nitrates such as, nitroglycerine, isosorbitol dinitrate, 













ridamole, dilaZep, trapidil, trimetazidine, and the like. Vaso 
constrictors such as, dihydroergotamine, dihydroergotoxine, 
and the like. B-blockers or antiarrhythmic agents such as, 
timolol pindolol, propranolol, and the like. Humoral agents 
Such as, the prostaglandins, natural and synthetic, for 
example PGE1, PGE2C, and PGF2C, and the PGE1 analog 
misoprostol. Antispasmodics such as, atropine, methanthe 
line, papaverine, cinnamedrine, methScopolamine, and the 
like. 
Calcium antagonists and other circulatory organ agents, 
Such as, aptopril, diltiazem, nifedipine, nicardipine, Vera 
pamil, bencyclane, ifenprodil tartarate, molsidomine, cloni 
dine, prazosin, and the like. Anti-convulsants such as, 
nitrazepam, meprobamate, phenyloin, and the like. Agents 
for dizziness such as, isoprenaline, betahistine, Scopolamine, 
and the like. Tranquilizers such as, reserprine, chlorprom 
azine, and antianxiety benzodiazepines such as, alprazolam, 
chlordiazepoxide, cloraZeptate, halazepam, oxazepam, 
prazepam, clonazepam, flurazepam, triazolam, lorazepam, 
diazepam, and the like. 
Antipsychotics such as, phenothiazines including thiopro 
pazate, chlorpromazine, triflupromazine, mesoridazine, pip 
erracetazine, thioridazine, acetophenazine, fluphenazine, 
perphenazine, trifluoperazine, and other major tranquilizers 
Such as, chlorprathixene, thiothixene, haloperidol, bromperi 
dol, loxapine, and molindone, as well as, those agents used at 
lower doses in the treatment of nausea, vomiting, and the like. 
Drugs for Parkinson's disease, spasticity, and acute muscle 
spasms such as levodopa, carbidopa, amantadine, apomor 
phine, bromocriptine, selegiline (deprenyl), trihexyphenidyl 
hydrochloride, benztropine mesylate, procyclidine hydro 
chloride, baclofen, diazepam, dantrolene, and the like. Res 
piratory agents such as, codeine, ephedrine, isoproterenol, 
dextromethorphan, orciprenaline, ipratropium bromide, 
cromglycic acid, and the like. Non-steroidal hormones or 
antihormones such as, corticotropin, oxytocin, vasopressin, 
salivary hormone, thyroid hormone, adrenal hormone, kal 
likrein, insulin, oxendolone, and the like. 
Vitamins such as, vitamins A, B, C, D, E and Kand deriva 
tives thereof, calciferols, mecobalamin, and the like for der 
matologically use. Enzymes Such as, lysozyme, urokinaze, 
and the like. Herb medicines or crude extracts such as, Aloe 
Vera, and the like. 
Antitumor agents such as, 5-fluorouracil and derivatives 
thereof, krestin, picibanil, ancitabine, cytarabine, and the 
like. Anti-estrogen oranti-hormoneagents such as, tamoxifen 
or human chorionic gonadotropin, and the like. Miotics such 
as pilocarpine, and the like. 
Cholinergic agonists such as, choline, acetylcholine, 
methacholine, carbachol, bethanechol, pilocarpine, muscar 
ine, arecoline, and the like. Antimuscarinic or muscarinic 
cholinergic blocking agents such as, atropine, Scopolamine, 
homatropine, methScopolamine, homatropine methylbro 
mide, methantheline, cyclopentolate, tropicamide, propan 
theline, anisotropine, dicyclomine, eucatropine, and the like. 
Mydriatics Such as, atropine, cyclopentolate, homatropine, 
Scopolamine, tropicamide, eucatropine, hydroxyamphet 
amine, and the like. Psychic energizers such as 3-(2-amino 
propy)indole, 3-(2-aminobutyl)indole, and the like. 
Antidepressant drugs such as, isocarboxazid, phenelzine, 
tranylcypromine, imipramine, amitriptyline, trimipramine, 
doxepin, desipramine, nortriptyline, protriptyline, amoxap 
ine, maprotiline, traZodone, and the like. 
Anti-diabetics such as, insulin, and anticancer drugs such 
as, tamoxifen, methotrexate, and the like. 
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Anorectic drugs such as, dextroamphetamine, metham 
phetamine, phenylpropanolamine, fenfluramine, diethylpro 
pion, mazindol, phentermine, and the like. 
Anti-malarials such as, the 4-aminoquinolines, alphamino 
quinolines, chloroquine, pyrimethamine, and the like. 
Anti-ulcerative agents such as, misoprostol, omeprazole, 
enprostil, and the like. Antiulcer agents such as, allantoin, 
aldioxa, alcloxa, N-methylscopolamine methylsuflate, and 
the like. Antidiabetics such as insulin, and the like. 
Anti-cancer agent Such as, cis-platin, actinomycin D, 
doxorubicin, Vincristine, vinblastine, etoposide, amsacrine, 
mitoxantrone, tenipaside, taxol. colchicine, cyclosporin A, 
phenothiazines or thioxantheres. 
For use with vaccines, one or more antigens, such as, 
natural, heat-killer, inactivated, synthetic, peptides and even 
T cell epitopes (e.g., GADE, DAGE, MAGE, etc.) and the 
like. 
Example therapeutic or active agents also include water 
soluble or poorly soluble drug of molecular weigh from 40 to 
1,100 including the following: Hydrocodone, Lexapro, Vico 
din, Effexor, Paxil, Wellbutrin, Bextra, Neurontin, Lipitor, 
Percocet, Oxycodone, Valium, Naproxen, Tramadol, 
Ambien, Oxycontin, Celebrex, Prednisone, Celexa, Ultracet, 
Protonix, Soma, Atenolol, Lisinopril, Lortab, Darvocet, 
Cipro, Levacquin, Ativan, Nexium, Cyclobenzaprine, Ultram, 
Alprazolam, Trazodone, Norvasc, Biaxin, Codeine, Clon 
azepam, Toprol, Zithromax, Diovan, Skelaxin, Klonopin, 
Lorazepam, Depakote, Diazepam, Albuterol, Topamax, Sero 
quel, Amoxicillin, Ritalin, Methadone, Augmentin, Zetia, 
Cephalexin, Prevacid, Flexeril, Synthroid, Promethazine, 
Phentermine, Metformin, Doxycycline, Aspirin, Remeron, 
Metoprolol, Amitriptyline, Advair, Ibuprofen, Hydrochlo 
rothiazide, Crestor, Acetaminophen, Concerta, Clonidine, 
Norco, Elavil, Abilify, Risperdal, Mobic, Ranitidine, Lasix, 
Fluoxetine, Coumadin, Diclofenac, Hydroxyzine, Phener 
gan, Lamictal, Verapamil, Guaifenesin, Aciphex. Furo 
semide, Entex, Metronidazole, Carisoprodol, Propoxyphene, 
Digoxin, Zanaflex, Clindamycin, Trileptal, Buspar, Keflex, 
Bactrim, Dilantin, Flomax, Benicar, Baclofen, Endocet, 
Avelox, Lotrel, Inderal, Provigil, Zantac, Fentanyl, Premarin, 
Penicillin, Claritin, Reglan, Enalapril, Tricor, Methotrexate, 
Pravachol, Amiodarone, Zelnorm, Erythromycin, Tegretol, 
Omeprazole, and Meclizine. 
The drugs mentioned above may be used in combination as 
required. Moreover, the above drugs may be used either in the 
free form or, if capable of forming salts, in the form of a salt 
with a suitable acid or base. If the drugs have a carboxyl 
group, their esters may be employed. The acid mentioned 
above may be an organic acid, for example, methanesulfonic 
acid, lactic acid, tartaric acid, fumaric acid, maleic acid, ace 
tic acid, or an inorganic acid, for example, hydrochloric acid, 
hydrobromic acid, phosphoric acid or sulfuric acid. The base 
may be an organic base, for example, ammonia, triethy 
lamine, or an inorganic base, for example, Sodium hydroxide 
or potassium hydroxide. The esters mentioned above may be 
alkyl esters, aryl esters, aralkyl esters, and the like. Also with 
Sugar to release as a bitterness masking agent (Sugar as the 
agent). 
The bioactive may also be administered, e.g., parenterally, 
intraperitoneally, intraspinally, intravenously, intramuscu 
larly, intravaginally, Subcutaneously, or intracerebrally. Dis 
persions may be prepared in glycerol, liquid polyethylene 
glycols, and mixtures thereof and in oils. Under ordinary 
conditions of storage and use, these preparations may contain 
a preservative to prevent the growth of microorganisms. 
Pharmaceutical compositions suitable for injectable use 













dispersions and sterile powders for the extemporaneous 
preparation of sterile injectable solutions or dispersion. In all 
cases, the composition must be sterile and must be fluid to the 
extent that easy Syringability exists. It must be stable under 
the conditions of manufacture and storage and must be pre 
served against the contaminating action of microorganisms 
Such as bacteria and fungi. The carrier may be a solvent or 
dispersion medium containing, for example, water, ethanol, 
poly-ol (for example, glycerol, propylene glycol, and liquid 
polyethylene glycol, and the like), Suitable mixtures thereof, 
and vegetable oils. 
The proper fluidity may be maintained, for example, by the 
use of a coating such as lecithin, by the maintenance of the 
required particle size in the case of dispersion and by the use 
of Surfactants. Prevention of the action of microorganisms 
may be achieved by various antibacterial and antifungal 
agents, for example, parabens, chlorobutanol, phenol, ascor 
bic acid, thimerosal, and the like. In many cases, it will be 
preferable to include isotonic agents, for example, Sugars, 
Sodium chloride, or polyalcohols such as mannitol and Sor 
bitol, in the composition. Prolonged absorption of the inject 
able compositions may be brought about by including in the 
composition an agent that delays absorption, for example, 
aluminum monostearate or gelatin. 
Sterile injectable solutions may be prepared by incorporat 
ing the therapeutic compound in the required amount in an 
appropriate solvent with one or a combination of ingredients 
enumerated above, as required, followed by filtered steriliza 
tion. Generally, dispersions are prepared by incorporating the 
therapeutic compound into a sterile carrier that contains a 
basic dispersion medium and the required other ingredients 
from those enumerated above. In the case of sterile powders 
for the preparation of sterile injectable solutions, the methods 
of preparation may include vacuum drying, spray drying, 
spray freezing and freeze-drying that yields a powder of the 
active ingredient (i.e., the therapeutic compound) plus any 
additional desired ingredient from a previously sterile-fil 
tered solution thereof. 
The bioactive may be orally administered, for example, 
with an inert diluent or an assimilable edible carrier. The 
therapeutic compound and other ingredients may also be 
enclosed in a hard or soft shell gelatin capsule, compressed 
into tablets, or incorporated directly into the subject’s diet. 
For oral therapeutic administration, the therapeutic com 
pound may be incorporated with excipients and used in the 
form of ingestible tablets, buccal tablets, troches, capsules, 
elixirs, Suspensions, syrups, wafers, and the like. The percent 
age of the therapeutic compound in the compositions and 
preparations may, of course, be varied as will be known to the 
skilled artisan. The amount of the therapeutic compound in 
Such therapeutically useful compositions is such that a Suit 
able dosage will be obtained. 
It is especially advantageous to formulate parenteral com 
positions in dosage unit form for ease of administration and 
uniformity of dosage. Dosage unit form as used herein refers 
to physically discrete units Suited as unitary dosages for the 
Subjects to be treated; each unit containing a predetermined 
quantity of therapeutic compound calculated to produce the 
desired therapeutic effect in association with the required 
pharmaceutical carrier. The specification for the dosage unit 
forms of the invention are dictated by and directly dependent 
on (a) the unique characteristics of the therapeutic compound 
and the particular therapeutic effect to be achieved, and (b) 
the limitations inherent in the art of compounding Such a 
therapeutic compound for the treatment of a selected condi 
tion in a subject. 
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Aqueous compositions of the present invention comprise 
an effective amount of the nanoparticle, nanofibril or 
nanoshell or chemical composition of the present invention 
dissolved and/or dispersed in a pharmaceutically acceptable 
carrier and/or aqueous medium. The biological material 
should be extensively dialyzed to remove undesired small 
molecular weight molecules and/or lyophilized for more 
ready formulation into a desired vehicle, where appropriate. 
The active compounds may generally be formulated for 
parenteral administration, e.g., formulated for injection via 
the intravenous, intramuscular, Subcutaneous, intralesional, 
and/or even intraperitoneal routes. The preparation of an 
aqueous composition that contain an effective amount of the 
nanoshell composition as an active component and/or ingre 
dient will be known to those of skill in the art in light of the 
present disclosure. Typically, such compositions may be pre 
pared as injectables, either as liquid Solutions and/or Suspen 
sions; Solid forms suitable for using to prepare solutions 
and/or Suspensions upon the addition of a liquid prior to 
injection may also be prepared; and/or the preparations may 
also be emulsified. 
The present inventor has developed methods and tech 
niques to form synthetic biomimetic networks, gels or poly 
mers that will bind and respond to specific molecules, ana 
lytes or moieties. These biomimetic polymer networks, gels 
or polymers are advantageous because they can be tailored to 
bind any molecule with controlled selectivity and affinity. 
There are some significant characteristics to consider in the 
design of a biomimetic polymer networks via a configura 
tional biomimetic imprinting (CBIP) technique. To achieve a 
relatively easy on/off binding event, a non-covalent recogni 
tion process is favored. Therefore, supramolecular interac 
tions, such as hydrogen bonding, electrostatic interactions, 
hydrophobic interactions, and van der Waals forces, are 
employed to achieve recognition. For the formation of the 
network, it is imperative that the functional monomers, 
crosslinker, and template are mutually soluble. In addition, 
the solvent must be chosen wisely, so that it does not interact 
and destabilize the self-assembled functional monomer and 
template. 
The ability to engineer traditional polymers with specific 
material properties is hampered by lack of control of molecu 
lar weight, chain configuration and polymerization kinetics. 
Hybrid materials have been developed to preserve the bulk 
properties of traditional polymers while making their 
molecular chains look more like proteins. The elusive goal of 
molecular recognition in Synthetic polymer systems has been 
reached in certain cases. Polyacrylic gels have been designed 
as with recognition capabilities by incorporating non-co 
valently crosslinked antibodies. These proteins couple the 
reversible swelling character of the networks with molecular 
recognition by only Swelling in the presence of a specific 
antigen. The advantage of using synthetic polymeric materi 
als based solely on proteins or peptides is the high degree of 
control over properties. Peptides and proteins can be coded 
for specific properties using a basic knowledge of inter and 
intrachain interactions. The present and future of biomedical 
materials development requires a degree of control prediction 
in design, synthesis and function of next generation materials. 
Recent work with this principle in mind has resulted in pro 
tein-based materials with properties analogous to more 
widely used polymers as well as new properties. These new 
materials have been generated with a variable degree of effi 
ciency and complexity. 
Examples of monomers that may be used to form polymers 
for use with the present invention include: Poly(allylamine), 













(Ethylamino)methacrylate, Methacrylic acid, methyl 
methacrylate, Triazacyclononane-copper(II) complex, 
2-(methacryloyxloxy)ethyl phosphate, methacrylamide, 
2-(trifluoromethyl)acrylic acid, 3-aminophenylboronic acid, 
poly(allylamine), o-phthalic dialdehyde, oleyl phenyl hydro 
gen phosphate, 4-vinylpyridine, vinylimidazole, 2-acryloila 
mido-2,2'-methopropane Sulfonic acid, Silica, organic 
silanes, N-(4-vinyl)-benzyliminodiacetic acid, Ni(II)-nitrilo 
triacetic acid, N-acryloyl-alanine. These monomers may be 
combined with one or more crosslinkers to achieve the 
desired low or minimal Swelling upon exposure to solvent 
alone that include: ethylene glycol dimethacrylate, pen 
taerythritol triacrylate, pentaerythritol tetraacrylate, trim 
ethylolpropane trimethacrylate, vinyl triethoxysilane, vinyl 
trimethoxysilane, toluene 2,4-diisocyanate, epichlorohydrin, 
triglycerolate diacrylate, polystyrene Surface, Propylene gly 
col dimethacrylate, poly(ethylene glycol) in dimethacrylate, 
methacrylate derived silica, acrylonitrile, N,N'-dimethy 
lacrylamide, poly(ethylene glycol)diacrylate. Examples of 
Solvents that may be used to achieve low or minimal Swelling 
include Acetonitrile, Acetic acid, ethanol, aqueous buffer, 
toluene, water, chloroform, hexane, methanol, tetrahydrofu 
a. 
The development of drug delivery vehicles requires sys 
tems that respond to a specific cue in the biological environ 
ment before the release of a drug payload. This is also coupled 
with the desire for such new devices to otherwise maintain 
structural integrity and avoid clearance from the body. We 
have described sensitive gels with stimuli-sensitive recogni 
tion very similar to recognition in proteins. By outlining the 
principles developed by analyzing theoretical mechanics of 
heteropolymers, the underlying memory of macromolecule 
conformation is discovered and empirically verified. Essen 
tially, their design includes polymerizing in the presence of 
target molecule, functional monomer, thermo-sensitive 
monomer, and end shielded post-crosslinking monomer. 
Some of these adsorption sites were destroyed upongel Swell 
ing and reformed upon shrinking. Important contributions 
have been made describing the nature of recognition in low 
cross-linked systems, and it is only a matter of time when 
intelligent gels can recognize other types of molecules. 
The present invention includes imprinted gels or chains 
possessing certain macromolecular architecture with binding 
abilities could be used as the sensing elements within analyte 
sensitive controlled release systems. Analyte sensitive poly 
mer networks have been the focus of much research (mostly 
saccharide recognition) and have been designed in a number 
of ways. 
Balancing pharmaceutical research for new drugs to treat 
human illness and disease with economic factors to minimize 
the cost of drug therapy has led to controlled and targeted drug 
delivery products. The goal of controlled drug delivery is to 
reduce the cost of treatment by allowing Smaller, yet equally 
effective, dosages through a regulating device. Some drugs 
have very short half-lives in the human body, and large doses 
of these drugs are metabolized rapidly, while other drugs, 
Such as many of the new protein drugs, are very fragile in the 
harsh environment inside the body. Controlled release 
devices can prolong the release time for the former, allowing 
effective dosages, and can protect sensitive drugs until the 
point where they are to be delivered. 
In the past, drug delivery devices have been limited to 
systems such as tablets, capsules, powders, droplets, oint 
ments and injections. Such systems while useful in treating 
Some diseases have certain disadvantages: (1) they are diffi 
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cult to regulate drug delivery; (2) they deliver their bioactive 
agent (drug) relatively fast; and (3) agent delivery is usually 
decreasing with time 
It must be noted that although the description above uses a 
drug as an active agent, similar problems have been observed 
with release of delivery of other active or bioactive agents, 
Such as (but not limited to): pesticides, herbicides, other agri 
cultural products, molluscicides, other marine biology prod 
ucts, agents that kill ticks, flees, etc., essential oils, perfumes, 
agents used in kitchen products, whitening agents used in 
laundry detergents. 
More recently, systems have been developed which allow 
controlled release of drugs to targeted areas of the body. Some 
methods used for the controlled delivery of drugs include: 
inserts and implants, transdermal systems, oral delivery sys 
tems, nasal delivery systems, vaginal delivery systems, rectal 
delivery systems, ocular delivery systems and bioadhesive/ 
mucoadhesive systems. 
Most of these systems while solving the problem of pro 
longed delivery of active agents, are not as efficacious in 
applications when the patient is unwilling or unable to take 
the necessary drug (payload) at a specific time or specific 
interval. More precisely, Such systems cannot control the 
problem of patient compliance, a significant problem in this 
industry. 
The use of carriers sensitive to the Surrounding environ 
ment, Such as pH-sensitive or temperature-sensitive systems 
have been reported in the field. Indeed, investigators have 
reported methods of delivering drugs, active agents and bio 
active agents in response to changes in pH or temperature of 
the surrounding fluid. 
Clearly, such systems can improve the pattern of delivery 
by being triggered to release their payload when a particular 
pH prevails in the Surrounding fluid. For example, numerous 
drug delivery systems have been patented where the passage 
from the stomach (low pH) to the upper small intestine (high 
pH) triggers the release of an active compound (drug). Often, 
Such systems are accompanied by selective targeting to vari 
ous tissue sites. For example, the so-called mucoadhesive 
drug delivery systems are based on polymeric materials 
which adhere to the mucin layer of a biological membrane for 
some length of time. The desired drug is loaded into the 
polymers. Once introduced to the body, the polymer carrier 
begins to Swell, allowing the release of the drug. Because the 
polymer binds to the mucin layer of the membrane, the drug 
is released locally and is thought to be able to absorb more 
easily across the membrane into the bloodstream. Some pos 
sible routes of administration for mucoadhesive systems 
include: the nasal, ocular, buccal, gastrointestinal, vaginal 
and rectal areas. 
There are several distinct advantages in using controlled 
release systems over other methods of drug delivery. First, the 
drug can be delivered at a relatively constant concentration. 
Thus, the drug concentration can be maintained at a level that 
is higher than the therapeutic level of the drug, but lower than 
the toxic level. In the case of tablets, the drug concentration 
steadily increases until all of the drug has been released. At 
this point the concentration of drug in the body may be above 
its toxic level. Once the drug has been released from the tablet 
the concentration decreases until a Subsequent dose is taken. 
A second advantage of this type of drug delivery is that the 
rate and time period of delivery can be controlled depending 
on the properties of the polymer system. 
However, the previous systems do not possess the addi 
tional advantage of intelligence of recognition of not just a 













centration of an external analyte, a compound with special 
desirable or undesirable properties. 
Most if not all of these systems, whether passive of pH- or 
T-sensitive have a structure that belongs to the category of 
hydrogels. Hydrogels are highly biocompatible which makes 
them appropriate for a number of pharmaceutical and medical 
(but also cosmetic, food and consumer) applications. In addi 
tion to drug delivery carriers, hydrogels are biomaterials used 
as contact lenses and scaffolds for tissue engineering appli 
cations to name only a few of the potential roles. The polymer 
network can contain homopolymers or copolymers with the 
chemical structure determining the properties of the hydro 
gel. 
The network structure of the hydrogel can be characterized 
by a number of parameters. Three parameters that I will 
discuss here are the polymer volume fraction in the swollen 
state, Va., the molecular weight between crosslinks, M. and 
the distance between crosslinks also known as the mesh size. 
The values for these parameters can be determined empiri 
cally or by theoretical calculations. 
The polymer fraction in the swollen state is a measure of 
how much water the hydrogel can imbibe when placed in an 
aqueous environment. The ability of hydrogels to retain large 
amounts of water makes them similar to natural tissue and 
may contribute to their high biocompatibility. Both the 
molecular weight and distance between crosslinks give an 
indication of how highly crosslinked the network is. Due to 
the randomness involved with polymer formation, these 
parameters can only be given as average values throughout 
the hydrogel. These parameters can indicate how much space 
is available for diffusion in and out of the hydrogel. This 
value, along with the size of the agent to be delivered, will be 
important in determining the release kinetics of the agent 
from the hydrogel in drug delivery applications. The degree 
of swelling present in the network will affect the mesh size 
and therefore a physiologically-responsive hydrogel that 
swells when presented with certain stimuli can have different 
release kinetics at different sites in the body. 
pH-Responsive hydrogels are composed of ionic networks 
and Swell in response to pH changes. This Swelling behavior 
is controlled by the ionization of the pendant groups in the 
network. Charged groups exhibit electrostatic repulsion that 
leads to imbibition of water and increased mesh size. This 
event also depends on the level of crosslinking present in the 
hydrogel. Highly crosslinked materials will not be able to 
Swell to as high a degree as materials with lower crosslinking 
ratios due to decreased chain mobility. The degree to which a 
hydrogel network will swell is also dependent upon the ability 
to imbibe water. Hydrogels with hydrophilic groups can 
imbibe more water than those with hydrophobic groups and 
can therefore swell to a greater extent. The hydrophobicity/ 
hydrophilicity of the network will therefore also have an 
impact on the diffusion of any compound embedded within a 
hydrogel network. An example of a monomer that will create 
anionic hydrogel with pH-responsive Swelling is methacrylic 
acid (MAA). When the pH of the environment is greater than 
the pKa of the carboxylic acid groups in MAA, they become 
ionized and cause interchain repulsion. The pKa of this group 
in poly(methacrylic acid) is approximately 4.9 making the pH 
shift from the stomach to upper small intestine (1.5-6) appro 
priate to change the ionization of the carboxyl groups. The 
charged groups are also hydrophilic and allow water to enter 
the network and continue the Swelling process. 
The process of ionization is reversible depending on the pH 
of the environment. If the MAA is grafted with another poly 
mer capable of forming hydrogen bonds, like poly(ethylene 
glycol) (PEG), then hydrogen bonds can form between the 
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chains when in the protonated state at low pH. This pH 
dependant formation of hydrogen bonds provides another 
means by which the network exists in a compact state at low 
pH and a more open state at the elevated pH. Hydrogels that 
exhibit this activity are termed pH-responsive complexation 
hydrogels. 
Through the use of monomers with side chains containing 
groups with pK values in the range desired, a pH-responsive 
hydrogel could be designed much in the same manner as 
enteric coatings. Hydrogels can exhibit Swelling to different 
degrees based on the intensity of the stimulus and this could 
be used to target release of multiple compounds at different 
sites. For example, if a hydrogel Swelled and increased it 
mesh size sufficiently to release a small compound at one pH 
and showed increased Swelling at a pH later in the gastrointes 
tinal tract, like the colon as opposed to the Small intestine, it 
could release a second larger agent at this location. The vari 
ability of the hydrogel delivery system in what it will respond 
to and how it will respond makes it an attractive candidate for 
numerous clinical applications including targeted drug deliv 
ery. 
These hydrogels can be used for delivery of a variety of 
therapeutic agents. For example, previous work in our labo 
ratory has focused on the use of hydrophilic polymer carriers 
for oral delivery of proteins such as insulin. The loading of 
proteins into the hydrogels was done by imbibition, where the 
polymer is Swollen in a solution containing the protein and 
collapsed at low pH to trap the protein inside. 
Recognitive Materials—Molecular Recognition. The rec 
ognition of a specific molecule out of a whole host of com 
peting species is essential to all life processes. It is this ability 
that allows for the proper functioning of enzymes, antibodies, 
receptors, and signaling molecules. Ultimately, the design of 
biomaterials will include this molecular recognition ability, 
whether it is a Smart system that recognizes only diseased 
cells, an implantable device with a tailored surface that does 
not elicit an immune response, or a sensor that can track levels 
of a specific compound in situ. In addition to use as bioma 
terials, the creation of synthetic materials with recognitive 
abilities will have great benefits in the areas of separations, 
assays, catalysis, and mass transport. 
Synthetic Systems for Molecular Recognition. Undoubt 
edly, methods for the creation of materials with recognitive 
abilities similar to those shown in biological molecules Such 
as enzymes and antibodies have been heavily sought after. 
Molecular Recognition with Crosslinked Networks. By 
crosslinking the polymer chains, it is possible to restrict the 
number of conformations a given chain may adopt. In the 
formation of a configurationally biomimetic imprinted poly 
mer (CBIP), interactions between a template molecule and 
the monomer feed molecules leads to the creation of a binding 
site that is Subsequently locked in by polymerization and 
crosslinking. To date, imprinted structures have been Success 
fully used in chromatographic applications 34-39, as sen 
sors 40-42, and even as catalytic elements 43-46. 
Wulff, et al. 34 demonstrated the first simple molecularly 
imprinted polymers (MIPs) utilizing monomers that had been 
covalently linked to the functional monomers in order to 
establish a proper 1:1 stoichiometric ratio. After polymeriza 
tion, the template molecule was freed through lysis. This 
covalent technique of imprinting has several advantages 
including efficient use of all available functional groups and a 
propensity to form a more uniform binding pocket, but is 
restrictive in what monomers may be used. A technique later 
pioneered in the laboratories of Mosbach involves imprinting 
a freely soluble template without the use of covalent linkages 
47, 48. This technique allows for greater flexibility in the 













However, reaction conditions need to be more strictly con 
trolled to maximize interaction between template and mono 
mer molecules. In addition, a number of different binding 
sites may form leading to Some nonspecific binding. 
The molecular imprinting procedure. The production of a 
Successfully imprinted polymer results in a material with 
recognitive properties. While many polymerization tech 
niques are amenable to the imprinting procedure, most utilize 
a free radical technique with either thermal, ultraviolet, or 
redox methods providing the initiating radicals 49. Com 
mon monomers include the methacrylate and acrylate family 
of molecules, acrylamides, and other vinyl derivatives as 
these are readily available, polymerize easily with the free 
radical technique, and are available with a number of func 
tional groups 50. In addition to monomer molecules with an 
array of functional groups, it is crucial to have crosslinking 
agents that incorporate well into the polymerization. Usually, 
a crosslinking agent is selected Such that it has similar reac 
tivity to the monomers used so as to form a network uniform 
in crosslinking density 51. 
The prepolymerization mixture includes the functional 
monomers, crosslinking agent, initiating species, template, 
and solvent if desired. As free radical polymerizations are 
sensitive to the presence of radical scavengers such as dis 
Solved oxygen, the mixture is first purged with an inert gas 
Such as nitrogen. Polymerization is then initiated. As Sug 
gested by Pande et al. 28 in their work on random het 
eropolymers, successful imprinting is more likely to occurat 
lower temperatures since entropic effects are lessened, which 
suggests the use of either a redox or UV initiation method. 
However, many groups have successfully used thermal ini 
tiation, albeit at lower temperatures than normally seen for 
thermal polymerizations. 
Following polymerization, the imprinted polymer is swol 
len in solvent to facilitate the removal of the template mol 
ecule. Often times before dialysis, the crosslinked material is 
crushed and sieved to produce particles of a given diameter in 
order to facilitate mass transfer. Once free of template, the 
MIPs are subjected to analysis of their binding ability through 
a variety of techniques including liquid chromatography, 
NMR, and microcalorimetry. 
Yu and Mosbach 35 studied the influence of crosslinking 
density on the recognitive ability of a non-covalently formed 
MIP imprinted for the separation of Boc-D-Trp and Boc-L- 
Trp enantiomers. In their studies, it was shown that the ability 
to separate enantiomers decreases as the crosslinking density 
is decreased. This supports work done by Wulff, et al. 52 
with covalently imprinted materials where in addition to a 
decrease in recognition, there was also a minimum amount of 
crosslinking needed for recognition. While increases in 
crosslinking density are favorable to the recognitive ability of 
a MIP, the resultant decrease in network mesh size may act to 
hinder diffusion through the network, especially limiting for 
the recognition of large molecules Such as proteins. 
Applications of molecularly imprinted materials. Histori 
cally, the main application of MIPs has been in chromato 
graphic uses. Crosslinked recognitive materials are formed 
with through the imprinting process and are then crushed into 
particles Suitable for packing into chromatographic columns 
49), or used in thin layer chromatography 37. The recog 
nitive ability of the particles allows for affinity chromatogra 
phy whereby only the compound of interest is bound by the 
column and all other species elute freely. This has worked 
especially well for the separation ofenantiomers, a classically 
difficult separation. In 1974, Wulff, et al., 34 first suggested 
the formation of configurationally biomimetic imprinted 
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polymers for the separation of D.L-glyceric acid. Since then, 
a significant amount of work has been focused on creating 
MIPs for separations, including enantiomers of Tryptophan 
derivatives by Yu and Mosbach 35, nicotine-like com 
pounds by Andersson et al. 36, D- and L-phenylalinine 
anilide by Kriz et al. 37, peniclin G and related compounds 
by Cederfur et al. 38, and amino acids by Kempe and Mos 
bach 39. 
More recently, MIPs have been employed as sensing ele 
ments due to their molecular recognition abilities. Due to the 
minute amounts typically bound, a highly sensitive quartz 
crystal microbalance (QCM) is used to determine the mass of 
analyte absorbed. Detection by QCM has been used by Haupt 
etal. 40 for the detection of R- and S-propanolol hydrochlo 
rides, by Liang et al. 41 for the detection of epinephrine, and 
by Hilt et al. 42 for the detection of D-glucose. 
Traditionally, the design of biomaterials has focused on 
biocompatibility—the propensity for a material to not invoke 
a foreign body response upon implantation or contact in the 
body. Numerous studies have been done to tailor surface 
properties so as to not elicit an immune response. The main 
method has been to functionalize the surface with a hydro 
philic molecule. Such as grafted poly(ethylene glycol) chains, 
to mask the foreign Surface from protein adsorption. How 
ever, it is now being recognized that molecular recognition 
may play an important role in future biomaterials design. 
Materials that show good biocompatibility are being further 
enhanced to include molecular recognition. Articles by Rat 
ner 53 and by Peppas and Langer 54 discuss how building 
recognitive abilities into biomaterials has the potential to 
radically advance the field. Potential applications include: (1) 
materials that invoke healing pathways to rebuild tissue in the 
implantation area; (2) combined sensing element/controlled 
release device to meter and release appropriate amounts of 
therapeutic compounds; (3) recognitive materials specific to 
toxins or deleterious signaling molecules (such as angio 
tensin) for rapid detoxification in the blood stream; and (4) 
antibody or enzyme mimics for in vivo use from Synthetic 
materials. 
Researchers working towards these goals have focused on 
the creation of materials that are suitable for use in the body 
yet interact with the biomolecule of interest. Byrne et al. 55, 
56 and used an imprinting technique to create hydrogels 
capable of binding D-glucose. This technique was later 
coupled with sensing technologies developed by Hilt et al. 
57 to form a microsensor capable of detecting D-glucose 
42. Other glucose responsive materials have been formed by 
Oral and Peppas 58 utilizing star polymers and by Parmpi 
and Kofinas 59. In addition to small biomolecules, Bolisay 
et al. prepared a configurationally biomimetic imprinted 
material suitable for the detection and screening of baculovi 
ruses 60. Molecular imprinting is well-known and can be 
conducted using one or more biomolecules, e.g., Acetalde 
hyde (metabolism byproduct); Adenine, adenosine 5V-triph 
osphate (ATP); Amino acid and peptide derivatives: Z-L-Tyr 
OH: Z-L-Phe-OH: Z-DL-Phe-OH: Z-L-Glu-OH; Boc-L- 
Phe-Gly-Oet; Z-L-Ala-L-Ala-OMe, Z-L-Ala-Gly-L-Phe 
OMe: Z-L-Phe-OH: Ampicillin (penicillin antibiotic); 
a-Amylase (enzyme); Angiotensin II (SA) (competitive 
inhibitor of peptide hormone angiotensin II); Bupivacaine 
(anaesthetic drug); Butein (active anti-EGFR inhibitor); Caf 
feine (stimulant drug); Cephalexin (antibiotic drug; in a-ami 
nocephalosporins class); Chlorphenamine (anti-histamine 
drug); Clenbuterol (hadrenergic blocker); Cortisone (ste 
roid); Creatine (metabolite); Creatinine (metabolite); Choles 
terol (steroid); Cholic acid sodium salt (bile acid); Carbohy 













lactose; cellobiose; Carbohydrate derivatives: octyl-gluco 
side; p-nitrophenyl fucoside, p-nitrophenylgalactoside; Per 
acetylated phenyla- and h-D-galactosides; Diazepam (i.e., 
Valium, benzodiazepine anxiolytic drug); Enkephalin (neu 
ropeptide); Ephedrine (stimulant drug); Epinephrine (adrena 
line hormone); Estradiol (estrogenic steroid hormone); Ethy 
nylestradiol (estrogenic steroid hormone derivative); 
9-ethyladenine (nucleotide base derivative): 9-ethyladenine 
acetate (nucleotide base derivative); Glucose oxidase (en 
Zyme); L-glutamine (amino acid); Histidine (N-terminal) 
dipeptides; Homocysteine (non-essential amino acid); 
Horseradish peroxidase (enzyme); Ibuprofen (non-steroidal 
anti-inflammatory drug); Ketoprofen (non-steroidal anti-in 
flammatory drug); Lysozyme (enzyme); Morphine (narcotic 
analgesic drug); Naproxen (non-steroidal anti-inflammatory 
drug); Nerve agent degradation products: (S)-nilvadipine (di 
hydropyridine calcium antagonists); Nucleoside base deriva 
tives: tri-O-acetyl adenosine; tri-O-acetyl guanosine; di-O- 
acetyl thymidine; tri-O-acetyl cytidine; tri-O-acetyluridine: 
Nucleotide base derivatives: 9-ethyladenine: 1-propyl thym 
ine; 1-propyl cytosine: 1-cyclohexyl uracil; Oxytocin (hor 
mone); Paracetamol (i.e., acetaminophen, analgesic); Pheny 
lalanine (amino acid); (E)-piceatannol (active anti-EGFR 
inhibitor); Propanolol (h adrenergic antagonist); Quercetin 
(active anti-EGFR inhibitor); Ribonuclease A (enzyme): 
Ricin A and B Chains (toxin bean lectin): (S)-ropivacaine 
(anaesthetic); Scopolamine (anti-cholinergic, anti-infective; 
and analgesic alkaloid drug); Sulfonamides (antibiotic drug); 
Testosterone (steroid hormone); Tetracycline (antibiotic 
drug); Theophylline (Bronchodilator drug); Timolol (hadr 
energic blocker); Trypsin (enzyme); Tyrosine (amino acid); 
Tyr-Pro-Leu-Gly-NH2 (tetrapeptide); Leu-enkephalin; Leu 
enkephalin; Morphine; Morphine: Ampicillin; S-propra 
nolol. D-phenylalanine; Adenine; 9-ethyladenine; 9-ethylad 
enine; 9-ethyladenine acetate; Cholesterol; Homocysteine: 
Trypsin; Theophylline; see, e.g., Hilt & Byne, Configura 
tional biomimesis in drug delivery: molecular imprinting of 
biologically significant molecule, Advanced Drug Delivery 
Reviews 56 (2004) 1599-1620, relevant portions and citations 
incorporated herein by reference. 
Protein Imprinting. The potential applications for a recog 
nitive material capable of binding a protein are numerous, 
including diagnostic devices for protein assays, systems for 
use in immunochemistry, and separation media for extremely 
complicated protein mixtures. Production of Such materials, 
however, is difficult for several reasons. First, it is known that 
the presence of water reduces the interactions between tem 
plate and monomer since the water molecules compete for 
hydrogen bonds 33. Most imprinting, therefore, is done in 
the presence of non-aqueous media. However, peptides and 
proteins are especially sensitive to differing solvent condi 
tions and may denature in harsh solvents. Secondly, the large 
diameter of protein molecules may preclude the use of a 
densely crosslinked polymeric network since the mesh size of 
the network is too small to allow for efficient diffusion. It is 
also unclear how selective a protein imprinted material can be 
made, and whether Subtle changes, such as the process of site 
directed mutagenesis, can be differentiated by these materi 
als. 
To date, several attempts have been made at creating MIPs 
for the recognition of oligopeptides and proteins. Shnek et al. 
61 and Kempe et al. 62 focused on a surface imprinting 
approach whereby monomers capable of complexing a metal 
ion were polymerized into a MIP for with an affinity for 
proteins with surface exposed histidine residues. Polymers 
imprinted in the bulk have been prepared for the recognition 
of peptides by Andersson etal 63 and for the recognition of 
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proteins by Venton and Gudipati 64. Recently, Rachkov and 
Minoura I65 have demonstrated a method where only a 
fragment of the protein is used in the imprinting process, 
leading to a site that is favorable for a portion of the whole 
protein. This so called “epitope approach’ mimics the ability 
of antibody molecules to recognize a portion of a protein 
Structure. 
Essential oils. Essential oils are complex mixtures of 
numerous compounds, they are aromatic oily liquid and can 
be extracted from various parts of the plants. Some of the 
main chemical groups found in essential oils include alco 
hols, aldehydes, esters, ethers, ketones, phenols and terpenes. 
Their use is mostly related to food as flavoring, to perfumes as 
fragrances and to pharmaceuticals for their functional prop 
erties. To date they are widely used as air freshener, several 
patents are reported dealing with their applications as deodor 
ant, Some are related to their use as good Smelling insect 
repellent. As reported in the review proposed by Burt (2004), 
antimicrobial properties of some essential oils have long been 
recognized; in particular they have been shown to exhibit 
antiviral, antimycotic, antitoxigenic, antiparasitic and insec 
ticidal properties. In the literature several works reports on 
their use to improve the shelf-life and safety of food and 
packaged food. 
Controlled release systems. As reported by Peppas and Am 
Ende (1997), the incorporation of fragrances in polymers for 
the purpose of controlled release over a period of 12 or more 
hours has been studied. Incorporation of essential oils in 
polymers could lead to new and innovative products for pro 
longed delivery of these compounds. Peppas and Brannon 
Peppas (1996) provided a wide view on papers dealing with 
the use of systems in which the fragrances are released from 
different matrices. In addition to those one, the release of 
linalool and linallyl acetate (the major components of aro 
matic lavender essential oils) from biopolymer gliadin-based 
nanoparticles (Duclairoir et al., 2002), the release of eucalyp 
tus essential oil from alginate complex capsule (Chang and 
Dobashi, 2003) and the release of limonene from polysaccha 
rides matrices (Secourad et al., 2003) were studied. Besides, 
Nakayama et al. (2003) studied the release of orange essential 
oils from temperature responsive membranes obtained by UV 
polymerization of mixture of N-isopropyl acrylamide and 
Polyethyleneglycole dimethacrylate. These references pro 
vide interesting information on the fragrance release mecha 
nism but, due to the requirements and characteristics of essen 
tial oils, Swelling-controlled release systems are highly 
desirable devices for Such applications, relevant portions 
incorporated herein by reference. 
The preparation of the above mentioned devices requires 
the understanding of the thermodynamic of the three-compo 
nents system, consisting of the polymer, the fragrance and the 
liquid which is usually in contact with the device. The release 
ofa fragrance initially embedded into the polymer matrix into 
the surrounding solvent is limited by several factors: the 
initial amount of fragrance loaded into the polymer, the Solu 
bility of the fragrance in the solvent, the equilibrium partition 
coefficient of the fragrance between polymer and solvent and 
the diffusional barrier. 
The present disclosure generally relates to biomimetic 
polymer network compositions, methods of forming Such 
polymer compositions, and methods of using Such composi 
tions. These compositions and have improved properties that 
make them useful for a variety of applications; in particular, 
the loading and delivery of therapeutic agents. 
The biomimetic polymer networks of the present disclo 
Sure generally include a polymer network having architec 













metic polymer networks may have shape specific cavities that 
match the moiety, as well as chemical groups oriented to form 
multiple complexation points with the moiety. In terms of 
selectivity, the resulting polymer networks are selective due 
to the particular chemistry of the binding site, the orientation 
and stabilization of the chemistry in a crosslinked matrix, as 
well as by the size and shape of the site for the template 
biomolecule. 
In some embodiments, the biomimetic polymer networks 
may further comprise a moiety. Such compositions may be 
capable of releasing the moiety in a relatively controlled 
fashion. The moiety may be present on a target compound, for 
example, a therapeutic agent. Accordingly, the compositions 
and methods of the present disclosure may be used in the 
treatment of a disease. For example, the compositions of the 
present disclosure may be used as a vehicle to deliver a 
therapeutic agent to a Subject (e.g., a human) in need thereof. 
The compositions of the present disclosure also may be used 
to form a medical device or an article. The present disclosure 
also provides methods of forming a biomimetic polymer net 
work of the present disclosure. 
The moiety may be any portion of a molecule recognized 
by a biomimetic polymer network of the present disclosure. 
The moiety may be covalently bound to a target compound, 
for example, a therapeutic agent. In this way, the moiety may 
be used to associate a target compound with a biomimetic 
polymer network of the present disclosure. The moiety 
should either already be present on the target compound or 
capable of being conjugated to a target compound. Conjuga 
tion of moieties to therapeutic agents is known in the art, for 
example, as disclosed in A. Wong and I. Toth, Curr: Med. 
Chem. 8:1123-36 (2001), the relevant disclosure of which is 
incorporated by reference. Examples of suitable moieties 
include, but are not limited, to Sugars (e.g., glucose), carbo 
hydrates, peptides, and functional groups. A specific example 
of a therapeutic agent that comprises a moiety is streptozoto 
cin (R. R. Herr, et al., J. Am. Chem. Soc. 89:4808-09 (1967)), 
which has a glucose moiety. 
In certain embodiments, the moiety is a Sugar. For 
example, the Sugar may be a monosaccharide. Monosaccha 
rides have the chemical formula (CH2O)n and the chemical 
structure H(CHOH)nC=O(CHOH)nH. If norm is zero, it is 
an aldose, otherwise it is a ketose. Monosaccharides may 
include aldoses, trioses (e.g., glyceraldehyde), tetroses (e.g., 
threose), pentoses (e.g., ribose, Xylose), hexoses (e.g. glu 
cose, fructose, mannose, galactose), ketoses, trioses, tetroses, 
pentoses (e.g., ribulose), hexoses (e.g., fructose). Any of the L 
and D isomers of a Sugar also may be used, although the D 
isomer may be more preferred for biological applications. 
Other examples of Suitable Sugars include polysaccharides. 
Polysaccharides have a general formula of C(H2O), where 
n is usually a large number up to 500. Disaccharides, such as, 
for example, Sucrose, lactose, maltose, and the like may be 
used. Yet another example of Suitable Sugars includes oli 
gosaccharides and low molecular weight carbohydrates (e.g., 
having a molecular weight no greater than about 2,000 Da). 
Further, each carbon atom that Supports a —OH group (ex 
cept for the first and last) is chiral, giving rise to a number of 
isomeric forms all with the same chemical formula. 
Specific embodiments may use the following monosaccha 
rides as moieties: monoses, dioses, trioses, tetroses, pentoses, 
aldo-pentoses, including arabinose, ribose, deoxyribose and 
Xylose, keto-pentoses including ribulose, hexoses including 
aldo-hexoses such as: allose, altrose, galactose, glucose, 
mannose and talose, and keto-hexoses such as fructose, hep 
toses including keto-heptoses such as mannoheptulose and 
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Sedoheptulose, octoses Such as octolose, 2-keto-3-deoxy 
manno-octonateand and nonoses such as Sialic acid. 
Specific embodiments may use mucopolysaccharides. 
Mucopolysaccharides are long unbranched polysaccharides 
consisting of a repeating disaccharide unit. This unit consists 
of an N-acetyl-hexosamine and a hexose or hexuronic acid, 
either or both of which may be sulfated. Members of this 
family vary in the type of hexosamine, hexose or hexuronic 
acid unit they contain e.g. glucuronic acid, iduronic acid, 
galactose, galactosamine, and glucosamine. They also vary in 
the geometry of the glycosidic linkage. Specific example 
polysaccharides that may be used as moieties include: chon 
droitin Sulphate, dermatan Sulphate, keratan Sulphate, hepa 
ran Sulphate, heparin, Sodium heparin, hyaluronic acid and 
hyaluronan. 
In other embodiments, the moiety may be a lipid or a short 
amino acid sequence (e.g., a sequence of about twenty amino 
acids in length). In particular, lectins may be used as a moiety. 
Lectins are carbohydrate-binding proteins involved in a vari 
ety of recognition processes and exhibit considerable struc 
tural diversity. A large variability in quaternary association 
resulting from Small alterations in essentially the same ter 
tiary structure is a property exhibited specially by legume 
lectins. The strategies used by lectins to generate carbohy 
drate specificity include the extensive use of water bridges, 
post-translational modification and oligomerization. Other 
carbohydrate-based structures may be used as moieties may 
be located at http://www.chem.cmul.ac.uk/iupac/2carbf (ac 
cessed Apr. 27, 2006), incorporated by reference herein. 
In general, the compositions of the present disclosure have 
enhanced affinities (e.g., impart greater affinity, bound ratios 
greater than 1) for a chosen moiety, among other things, 
allowing for increased loading efficiency. Accordingly, the 
compositions of the present disclosure also may be used to 
increase the loading of a target compound or control the 
release rate of a target compound or both. The compositions 
of the present disclosure also may be used for delivery of a 
therapeutic agent. For example, the compositions of the 
present disclosure may be used as an excipient or as a vehicle 
for a therapeutic agent. Specifically, higher quantities of a 
therapeutic agent having a moiety can be loaded within the 
biomimetic polymer networks of the present disclosure, 
therefore enabling for higher doses to be loaded. The release 
of a moiety may be tailored to give a desired release profile, 
for example, for Sustained release of a therapeutic agent. 
Thus, when the moiety is bound to a therapeutic agent, treat 
ment with the therapeutic agent may be optimized. 
The compositions of the present disclosure may beformed 
using configurational biomimetic imprinting. Configuration 
biomimetic imprinting techniques generally involve forming 
a prepolymerization complex between the template molecule 
(e.g., a moiety) and functional monomers or functional oli 
gomers (or polymers) with specific chemical structures 
designed to interact with the template either by covalent 
chemistry or noncovalent chemistry (self-assembly) or both. 
Once the prepolymerization complex is formed, the polymer 
ization reaction occurs in the presence of a crosslinking 
monomer and an appropriate solvent, which controls the 
overall polymer morphology and macroporous structure. 
Once the template is removed, the product is a heteropolymer 
network with specific recognition elements for the template 
molecule. 
The network structure depends upon the type of monomer 
chemistry (i.e., anionic, cationic, neutral, amphiphilic), the 
association strength and number of interactions between the 
monomers and template molecule, the association interac 













type and the amount of solvent in the mixture, the reactivity 
ratios of the monomers, and the relative amounts of reacted 
monomer species in the structure. Since noncovalent forces 
are weaker than covalent bonds, an increased number of 
interactions are needed for stable binding and recognition. On 
a per-bond basis, noncovalent bonds are 1-3 orders of mag 
nitude weaker. Therefore, a greater number of noncovalent 
bonding with matching structural orientation is needed for 
aqueous recognition. 
A wide variety of polymers may be used to form the het 
eropolymer network. These include polymers produced by 
reaction of acrylamides and all their substituted structures 
including: methacrylamide, ethacrylamide, isopropyl acryla 
mide, etc., acrylic acid, methacrylic acid, ethacrylic acid, all 
alkyl acrylic acids, any dicarboxylic acid, such as crotonic 
acid, phthalic and terephthalic acid any tricarboxylic acid 
with itself another monomer of the above list (forming a 
copolymer), two other monomers from the above list (form 
ing terpolymers), or three or more monomers from the above 
list forming higher order coploymers. The above may be in 
linear, branched or grafted form, the grafted chains being 
exclusively one polymer or copolymers of the above, ioni 
cally bound or complexed by hydrogen bonds. 
The above may be crosslinked in the presence of crosslink 
ing agents to form insoluble but Swellable gels or networks, 
having the ability to absorb water, physiological fluids, buff 
ers or salt solutions with final swelling as low as 1 weight% 
of water and as high as 99.9% water. 
The above crosslinking may be achieved with ethylene 
glycol dimethacrylate, ethylene glycol diacrylate, ethylene 
glycol trimethacrylate, ethylene glycol diacrylate, ethylene 
glycol multi methacrylate where “multi” stands for n=4 to 
200 units ethylene glycol multi acrylate where “multi’ stands 
for n=4 to 200 units same as above but propylene glycol multi 
methacrylate where “multi’ stands for n=1 to 200 units same 
as above but alkylene glycol multi methacrylate where 
“multi’ stands for n=1 to 200 units. One may also use higher 
order acrylates and methacrylates including but not limited to 
1.1.1 trimethylolethane trimethacrylate (TrMETrMA, 
Molecular Weight 324.4); 1,1,1 trimethylolpropane triacry 
late (TrMPTrA, Molecular Weight 296.3); 1,1,1 trimethylol 
propane trimethacrylate (TrMPTrMA, Molecular Weight 
338.4): pentaerythritol triacrylate (PETrA, Molecular Weight 
298.3); glycerol propoxy triacrylate (GlyPTrA, Molecular 
Weight 428.5); pentaerythritol tetraacrylate (PETeA, 
Molecular Weight 353.2); ethoxylated 1.1.1 trimethylolpro 
pane triacrylate (ETrMPTrA, Molecular Weight 428); glyc 
erol propoxylated triacrylate (GlyPTrA, Molecular Weight 
428) and glycerol trimethacrylate (GlyTrMA, Molecular 
Weight 396.3). One may also use with “star polymers' or 
“dendrimers' with up to 72 independent chains ending in 
acrylates or methacrylates. 
The initiator may be IRGACURE(R) products of the Ciba 
Geigy company including IRGACURE 184, IRGACURE(R) 
379, Ciba-R IRGACURER 819, and Ciba-R IRGACURER) 
250. Any other photoinitiator may also be used. The initiator 
may also be any peroxide including but not limited to benzoyl 
peroxide, cumyl peroxide, etc. or AZobis isobutyronitrile. 
In some embodiments, the biomimetic polymer network of 
the present disclosure may be formed using a template mol 
ecule (e.g., D-glucose) and functional monomers selected to 
match corresponding template molecule (e.g., glucose bind 
ing protein residues, such as aspartate, glutamate, and aspar 
agines, as well as biological mechanisms of action that 
involve recognition The template molecule may be added in 
Stoichiometric amounts in regard to the functionality of the 
template molecule. Since solvent interaction can stabilize or 
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destabilize binding in noncovalent systems, functional mono 
mers may be selected based on optimizing specific noncova 
lent, self-assembly interactions (hydrogen bonding) with the 
template molecule within an aprotic solvent (e.g., dimethyl 
Sulfoxide). Such techniques are generally applicable to tem 
plate molecules, in which hydrogenbonding, hydrophobic, or 
ionic contributions will direct recognition of the moiety. The 
formation of an exemplary biomimetic polymer network of 
the present disclosure according to the methods of the present 
disclosure is described below. 
The multilayered mimetic structures may be constructed 
from a variety of coating processes, including pan coating, 
air-Suspension coating, centrifugal extrusion, vibrational 
noZZle coating, Supercritical fluid (SCF) based processing, 
fluidization (both conventional Wurster coaters such as the 
Glatt device) and rotating, or spray-drying. 
The multilayered mimetic structures shown in FIGS. 1-2 
may be constructed using a Grow Max Spouted bed assisted 
with a draft tube and a bottom spray, also known as the 
Wurster configuration. The height of the bed is 535 mm and 
the diameter of the bed is 160 mm at the bottom and 300 mm 
at the top. 
The bed is equipped with a sampling port to allow the 
microcapsule to be withdrawn and analyzed during the coat 
ing process. The bed is also equipped with a viewing window 
to allow the observation of the fluidizing microcapsule during 
the coating process. The length of the draft tube to be used is 
preferably 200 mm and is located 15 mm above the air dis 
tributor. The diameter of the draft tube is 70 mm. The pneu 
matic spray noZZle with a liquid caliber of 1.0 mm can be used 
to atomize the dispersion fed to the bed. Abag filter with 5um 
opening can be used to prevent the microcapsules from escap 
ing through the top of the bed. The bag filter must be shaken 
frequently to prevent the microcapsule from adhering to the 
bag filter. The schematic diagram of the Wurster bed appara 
tus is shown in FIG. 2. 
The advantages of the Wurster process compared to con 
ventional fluidized bed process are: (i) the high inertia intro 
duced in the Wurster process to circulate the particles pre 
vents the agglomeration of the particles and (ii) the recycling 
profile creates a uniform coat around the particles. The circu 
lating pattern of the particles inside a Wurster bed is made 
possible by a draft tube. The air inlet is concentrated just 
under the draft tube. This creates a high air velocity inside the 
draft tube and a vacuum like effect at the base of the draft tube. 
The particles collected under the bed are readily pulled by the 
air inlet into the draft tube and being carried to the top of the 
bed. At the exit of the draft tube, there is a sudden expansion, 
from the diameter of the draft tube to the diameter of the 
chamber. This expansion causes the particle to lose its veloc 
ity gradually and finally gravity will pull the particles back 
down along the wall of the chamber to the base and the 
process will be repeated. 
Generally, a Wurster bed is equipped with a bottom spray, 
and hence, every time the particles pass through the based of 
the draft tube, latex dispersion will be sprayed on the par 
ticles. This process repeats every time the particles pass 
through the bottom of the draft tube, and finally, a uniform 
coating can be obtained. The ability to coat such small par 
ticles uniformly has broadened the applications of the 
Wurster process for particulate drug delivery systems. 
The Wurster coating process employed in the present dis 
closure is very versatile and can be applied for many different 
materials. The process has been shown to work for many 
different type of cores including calcium carbonate crystal, 
glass beads and lactose 1-6. Many latex dispersions have 













Such as poly(ethyl acrylate/methyl methacrylate/2-hydroxy 
ethyl methacrylate) (P(EA/MMA/HEMA)), composite latex 
of core P(EA/MMA/HEMA) and P(NIPAAm) shell, 
crosslinked P(NIPAAm), Eudragit RS30D, L30D-55 and 
FS30D, and ethyl cellulose 1-6). 
The Wurster coating process is a very harsh process. The 
process involves exposure to high temperature and high shear 
stress. The process requires high temperature to dry the 
coated microcapsules. The high shear stress is required to 
atomize the latex dispersion before being sprayed on the 
circulating microcapsules. Fortunately, the MIP nanopar 
ticles have shown promising stability at high temperatures 
and high shear stresses. 
One problem encountered with the coating process is the 
formation of a 'snowman-like' structure due to agglomera 
tion. These structures are produced by the fusion of two 
microcapsules. This fused structure creates weak spot along 
the contact point of the two microcapsules. Agglomeration 
prevents the formation of a single core microcapsule, which is 
the structure desired in this work. Several factors that affect 
the degree of agglomeration using the Wurster bed include: 
the feed rate of the latex dispersion, the flow rate of the dried 
air to fluidize the microcapsule and the temperature of the 
inlet air, the outlet air and the bed and the like. 
As used herein, the term “recognitive polymer refers to a 
network structure of polymeric layers that swell to release 
active agents within the polymer based on a number of fac 
tors, including: the type of monomer chemistry (i.e., anionic, 
cationic, neutral, amphiphilic), the association strength and 
number of interactions between the monomers and template 
or recognitive molecule used at the time that the polymer is 
formed, the association interactions between monomers and 
pendent groups, the solvent type and the amount of solvent in 
the mixture, the reactivity ratios of the monomers, and the 
relative amounts of reacted monomer species in the structure. 
Since noncovalent forces are weaker than covalent bonds, an 
increased number of interactions are needed for stable bind 
ing and recognition. On a per-bond basis, noncovalent bonds 
are 1-3 orders of magnitude weaker. Therefore, a greater 
number of noncovalent bonding with matching structural ori 
entation is needed for aqueous recognition. 
In the present invention, the multi-layer tablet includes a 
“swelling front” that separates the rubbery region (region of 
swollen CBIP/HPMC with enough water to have its T. below 
the experimental temperature) and the 'glassy region (re 
gion where the CBIP/HPMC has a Tabove the experimental 
temperature). 
A wide variety of polymers may be used to form multilay 
ered structures. These include polymers produced by reaction 
of acrylamides and all their Substituted structures including: 
methacrylamide, ethacrylamide, isopropyl acrylamide, etc., 
acrylic acid, methacrylic acid, ethacrylic acid, all alkyl 
acrylic acids, any dicarboxylic acid. Such as crotonic acid, 
phthalic and terephthalic acid any tricarboxylic acid with 
itself another monomer of the above list (forming a copoly 
mer), two other monomers from the above list (forming ter 
polymers), or three or more monomers from the above list 
forming higher order coploymers. The above may be inlinear, 
branched or grafted form, the grafted chains being exclu 
sively one polymer or copolymers of the above, ionically 
bound or complexed by hydrogen bonds. For application in 
organisms, such as humans, the polymers that will have most 
application are those that are biocompatible, and in some 
cases, also biodegradable. 
EXAMPLE 1. 
Recognitive/responsive tablet systems. Recognitive sys 
tems that show diffusional times that are much shorter than 
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for films were development by using multilayered tablets 
produced from recognitive particles that had been com 
pressed by 'standard pharmaceutical techniques. Swelling 
of hydrophilic polymeric tablets has been the subject of sig 
nificant research in the last few years. Of particular interest 
are studies on the Swelling and Subsequent dissolution of 
hydroxypropyl methyl cellulose (HPMC) tablets. 
Molecularly, individual chains absorb water so that their 
end-to-end distance and radius of gyration expand to the new 
Solvated State. This expansion (Swelling) is observed macro 
scopically by the formation of distinct fronts separating 
unswollen and Swollen regions. In the macroscopic observa 
tion of the swelling process we have identified a “swelling 
front” which clearly separates the rubbery region (region of 
swollen CBIP/HPMC with enough water to have its Tg below 
the experimental temperature) and the glassy region (region 
where the CBIP/HPMC has a Tg above the experimental 
temperature). A second front is the “erosion front” which 
separates the matrix from the solvent (glucose solution or 
water). 
The rupture lines due to the recognition process as well as 
the gel layer formed on the glassy core of a Swellable matrix 
are considered to be controlling elements of drug release 
kinetics, although other mechanisms may be functional in 
Such systems. The gel layer structure changes during tablet 
Swelling, due to the molecular extension of the Solvated poly 
meric chains. The diffusion front position in the gel phase 
during drug release is usually dependent on drug solubility 
and loading. In fact, the diffusion front movement can be 
related to drug dissolution rate. 
Preparation of Particles from Recognitive Polymers. The 
typical procedure of creating the particles from recognitive 
polymers includes MAA crosslinked with EGDMA around 
D-glucose, combined with deionized water, ethanol, and 
DMPA. Generally, the percentages were MAA: 3.25 wt %, 
D-glucose: 1.5 wt %, DI water: 31 wt %, Ethanol: 36 wt %, 
EGDMA: 28 wt %, DMPA: <1 wt %. Some solutions con 
tained more ethanol or less EGDMA in order to obtain a more 
continuous film. 
After the recognitive films were polymerized for 30 min 
utes in the UV lamp box, they were washed in deionized water 
(DI water) for 24-48 hours on average. Once taken out of the 
water, the films were placed in ventilated containers (two 
weigh-boats taped together with holes along top) and placed 
in a vacuum oven set at 30 C for at least 24 hours. After the 
films were completely dry, they were taken out of the oven 
and then crushed using a mortar and pestle until a very fine 
powder was produced; the goal was to try and get all the 
crushed particles to be the same size (roughly 100 microme 
ters). 
Preparation of Control Samples. All control samples were 
prepared the exact same way as recognitive polymers, except 
without adding D-glucose to the monomer Solution. The same 
procedures were used minus the D-glucose amounts. 
Preparation of Tablets by Compression. There were vari 
ous procedures for forming the mixture used in tablet com 
pression. The first few procedures did not form durable, last 
ing tablets because the amounts of binders andfillers were too 
Small or were not in the correct ratio. However, once a pro 
cedure produced tablets that remained intact, similar formu 
las and methods were used. 
According to the first protocol developed, reliable tablets 
were produced using 53.9 wt % CBIP microparticles, 10.9 
wt % microcrystalline cellulose, 34.4 wt % Poly(N-vinyl-2- 
pyrrolidone) (PNVP) K-25, a binder, and less than 1 wt % 
magnesium Stearate, a lubricant (Table 1). The total weight 














polymers were weighed and mixed with microcrystalline cel 
lulose in a weigh-boat using a spatula. A solution of 20% 
PNVP was made by combining 4 mg. PNVP in 20 ml deion 
ized water. A sample of 1 ml of 20% PNVP solution was 
added to weigh-boat drop-by-drop using a 1000-ml micropi 
pette. The mixture was then stirred with the spatula and 
placed on a hotplate at a very low temperature to allow liquid 
to evaporate. Before the mixture was completely dry, it was 
pushed through a metal sieve into granules. These granules 
were then placed in a ventilated container in a vacuum oven to 
completely dry. Once the granules were completely dry, the 
magnesium Stearate was added to the mixture and stirred with 
a spatula to get a homogenous mixture. This microparticle 
mixture was then weighed into 20-23 mg samples that would 
be the recognitive layers of each tablet. Bovine serum albu 
min was weighed into 5-6 mg samples to be used in between 
the recognitive layers (instead of insulin). 
The tablets were compressed using a Corning tablet press 
and a 6.33 mm diameter punch with flat edges; the pressure 
was 6000 N/inch. The first recognitive layer was a 20-23 mg 
sample of microparticle mixture placed inside the lower 
punch area and compressed; it was then left in the bottom as 
the additional layers were added. A 5-6 mg sample of bovine 
serum albumin (BSA) was then poured on top of this first 
recognitive layer. A Smaller punch was used lightly with a 
hand to even out this layer so it is as flat as possible. It was then 
compressed with the top punch so that both layers become 
one unit. This procedure was repeated until 5 recognitive 
layers and 4 BSA layers were pressed all together (creating a 
9-layer tablet). 
Similar mixtures were made in Smaller amounts using 66.0 
wt % microparticles, 5.9 wt % cellulose microcrystalline, 
27.3 wt % PNVP K-25, and <1 wt % magnesium stearate 
(Table 2). Another mixture was made using 86.2 wt % micro 
particles, 12.6 wt % PNVP K-25, and 1 wt % magnesium 
stearate (Table 3). 
From the previous data, a new mixture was made in order 
to produce thinner tablets without using a wider punch. This 
mixture included 74.3 wt % recognitive microparticles, 5.0 
wt % cellulose microcrystalline, 19.7 wt % PNVP K-25, and 
<1 wt % Magnesium Stearate (Table 4). The total weight was 
405 mg. This mixture followed the same procedures as 
before, except it was completely dry before pushed through 
the sieve in order to recover more particles/granules. This 
time only 7-layer tablets were pressed. In the Bovine Serum 
Albumin layers, a 1:1 mixture of Bovine Serum Albumin: 
Hydroxypropylmethylcellulose (HPMC) was used. The rec 
ognitive layers were between 10-12 mg and the BSA layers 
between 5-6 mg. 
TABLE 1 
Multilayered Tablet Sample No 1. 
Mass Percent 
(g) (%) 
Microparticle O.31364 53.8771 
Cellulose, microcrystalline O.O6345 10.8994 
PNVP (K-25) O.2OOOO 34.3560 
Magnesium stearate O.OOSOS O.86749 
Total Mass (g) O.S8214 1OO 
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TABLE 2 
Multilayered Tablet Sample No 2 
Mass Percent 
(g) (%) 
Microparticles (BLE36) O.O7970 65.9604 
Cellulose, microcrystalline O.OO708 5.85947 
PNVP (K-25) O.O33OO 27.3110 
Magnesium stearate O.OO 105 O.86898 
Total mass O.12083 1OO 
TABLE 3 
Multilayered Tablet Sample No 3 
Mass Percent 
(g) (%) 
Microparticles (BLE48) O.O3428 86.17396 
PNVP (K-25) O.OOSO 12.S6913 
Magnesium Stearate O.OOOS 1.256913 
Total mass O.O3978 100 
TABLE 4 
Multilayered Tablet Sample No 4 
Mass Percent 
(g) (%) 
Microparticles O.30096 74.29644 
Cellulose Microcrystalline O.O2O18 4.98.1732 
PNVP (K-25) O.08 19.74919 
Magnesium Stearate O.OO394 O.972647 
Total mass O.40508 1OO 
Summary of Prepared Samples. The first set of studies 
produced useful tablets in the form of thick multilayer tablets 
(minitablets). The total weights and thickness were 134.23 
mg, 3.11 mm; 137.2 mg, 3.42 mm; 132.31 mg, 3.4 mm (FIG. 
1). For single-layer tablets, the thickness was 0.58 mm, 0.63 
mm, 0.68 mm, and 0.65 mm. It was possible to observe the 
different layers and even particulate aggregates in these tab 
lets (FIG. 2). These tablets were very sturdy and did not break 
apart when handled. The second and third tablet recipes used 
higher amount of CBIP microparticles. One recipe without 
microcrystalline cellulose showed promising results using 
less of the mixture. 
Single-layer tablets made without microcrystalline cellu 
lose were thicker than the others because cellulose has a good 
compressibility. These tablets crumbled faster than other tab 
lets, possibly because the PNVP was not a sufficient binder to 
keep all the particles together as one unit. 
The tablet recipe with 5 wt % cellulose and 20 wt % PNVP 
produced much thinner disks (FIG.3a). The total weights and 
thickness were 58.25 mg, 1.55 mm; 59.79 mg, 1.46 mm: 
58.47 mg, 1.55 mm; 59.27 mg, 1.63 mm; 60.4 mg, 1.73 mm. 
For single-layer tablets, the thickness was 0.39 mm and 0.34 
mm (FIG. 3b). 
Most tablets made from the above recipes were sturdy and 
did not crumble when handled; only the verythin single-layer 
tablets seemed to fall apart when stress was applied. They all 
had a light-brownish hint to them, probably from the PNVP in 
the mixture. All edges were distinct and made perfect circles 













Observation of Swelling Process. One set of experiments 
was run, in which two single-layer tablets with 10 wt % 
cellulose and 34 wt % PNVP (first recipe) were put into 
separate beakers, one with DI water and the other with 100 
mg/dL D-glucose in DI water. These tablets were both 
approximately 0.66 mm thick. Both floated on the top of the 
liquids until rupture and/or swelling. After 20 minutes, the 
tablets in DI water started crumbling and breaking apart (FIG. 
4a). After 30 minutes, the tablets in 100 mg/dL glucose 
cracked down the middle, but did not crumble and fall to the 
bottom of the beaker. These tablets were still floating and did 
not crack significantly more after 60 minutes (FIG. 4b). After 
18 hours, both tablets had crumbled and landed in big clumps 
in the bottom of each beaker (FIGS. 5a and 5b). 
Another set of studies used a 9-layer tablet coated with 
PVA along the lateral area. This tablet was placed in a 50 ml 
beaker with 40 ml of 100 mg/dL glucose solution. The tablet 
was dropped into the beaker so that one of the recognitive 
sides was touching the bottom. After about 6 minutes, the first 
recognitive layer absorbed glucose and started responding by 
cracking and Swelling along top half began Swelling (FIGS. 
6a and 6b). Tiny bubbles were observed on the tablet, but it is 
not clear whether these were from the inside of tablet or 
formed after the tablet was dropped into the solution. After 13 
minutes, a large piece crumbled off the top and landed on the 
bottom. After several hours, the tablet had disintegrated 
(FIGS. 7a and 7b). There were little pieces scattered all along 
the bottom (FIGS. 8a and 8b). 
TABLE 5 
Below are the data regarding the novel 
multi-layer recognitive systems: 
Multilayer Multilayer Multilayer 
Tablet 1 Tablet 2 Tablet 3 
Layer Mass (mg) Mass (mg) Mass (mg) 
Disk 1 21.6 23.45 22.54 
Bovine Album in 1 5.8 6.84 6.25 
Disk 2 20.88 2212 21.79 
Bovine Albumin 2 6.26 6.03 6.56 
Disk3 21.74 22.7 20.67 
Bovine Albumin 3 6.22 6.33 5.83 
Disk 4 2212 21.46 21.68 
Bovine Albumin 4 6.8 5.64 5.95 
Disk 5 2281 22.63 21.04 
Total mass (mg) 134.23 137.2 132.31 
Thickness (mm) 3.11 3.42 3.4 
TABLE 6 
Formula for each disk 
Mass (g) Percent 
CBIP microparticle O31364 53.877O7 
cellulose, microcrystalline O.O6345 10.89944 
PNVP (K-25) O.2 34.356 
Magnesium Stearate O.OOSOS O.86.7489 
Total Mass (g) O.S8214 
27 
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Data Recipes for other various mixtures: 
Added (ml) # moles % mol (chemicals) % Wiw 
BLE4 recipe from 051707 (Zach Hilt's original recipe) 
5 
% mol 




MAA O431 O.OOSOO8 42.18806139 3.95790.588 
D-glucose O.1847 O.OO1025 1.696.11419 
15 
DI water 4.80O38 O.266,392 44.08.225575 
ethanol 4.1998.47 O.O91162 38.5675154 
EGDMA 1.235 O.OO6712 S6. S4O90759 11.34109922 
DMPA O.O3867 O.OOO151 1.271031026 O.3SS10956 
2O 
total mass: 10.889597 
moles: O.O11871 
Added to 
B (g) 25 
MAA O438 O.OOSO89 27.72581374 3.6254.11552 
D-glucose O.1909S O.OO106 1.58053O447 
DI water 4.80O38 O.266,392 39.7336829 30 
















































































Data/Recipes for other various mixtures: 
Added (g) Added (ml) # moles % mol (chemicals) % ww MW g/mol 
ethanol 7.101 9 O.15413S 30.314298 
EGDMA 7.0832 O.O38496 79.46OO1886 30.238.309 
DMPA O.O6068 O.OOO237 O4887.09626 O.259044 
total mass: 23.42459 
moles chemicals: O.048.447 
Recipe for BLE62 CBIP made 070507 
MAA O4495 O.OOS223 22.702351 3.SS44049 
D-glucose O.1898 O.OO 1054 1. SOO8366 
DI water 3.992 4 O.221532 31.566595 
ethanol 4.734 6 0.102757 37.433.933 
EGDMA 3.2499 O.O17663 76.77055044 25.6984.66 
DMPA O.O3108 O.OOO121 0.527098.559 O.245,764 
total mass: 12.64628 
moles chemicals: O.O23007 
Preparation of Samples. The control samples for these 
studies with multilaminate systems involved the creation of a 
7- or 9-layer “sandwich' similar in composition to the mul 
tilayer tablet systems using continuous films or discs (i.e., 25 
recognitive layer, followed by the bovine serum albumin, 
followed by another recognitive layer, etc. . . . ). In this case, 
however, instead of the recognitive layers, non-imprinted 
polymer film layers were used (thus preventing any specific 
recognition of glucose). 30 
Preparation of Multilaminate Systems. The multilaminate 
systems were developed in the same way as the multilayer 
tablets, with alternating layers of recognitive film and bovine 
serum albumin (used in our experiments in the place of a drug 
Such as insulin). 35 
The just-washed polymer films (created using the protocol 
discussed in Section I of this report) were cut into 8 mm 
(diameter) circles using a cork borer and were Subsequently 
dried in the vacuum oven. The dried circles were then stacked 
together (in a dry environment at room temperature) with a 40 
layer of bovine albumin serum in between each one (used in 
our experiment in the place of a drug such as insulin). Once 
the 7- or 9-layer stack was formed, room temperature Vulca 
nized (RTV) rubber was applied along the circumference of 
the stack using a toothpick, after which the system was left to 45 
dry for at least 24 hours. 
Parameters and Layers. The structure of the multilaminate 
system. In these studies, Small amounts of bovine serum 
albumin were used sufficient to fully cover the discs of the 
recognitive films below them. FIG.9 shows a diagram of the 50 
several layers of a multilaminate system of the present inven 
tion. The amount of BSA/drug to be placed between recog 
nitive layers will depend on the rate of diffusion of water 
inward and the rate of disintegration of the recognitive layers 
(among many other things). 55 
The following amounts were used: 
TABLE 9 
Layer Amount 60 
Bottom Disk 1 0.007 28 g 
BSA 1 0.00061 g 
Disk 2 0.00659 g 
BSA 2 0.00294g 
Disk 3 0.00626g 
BSA 3 0.00438g 65 
Disk 4 0.00596g 
TABLE 9-continued 
Layer Amount 
BSA 4 0.00512g 
Top Disk 5 0.00627g 
TABLE 10 
Layer Amount 
Bottom Disk 1 0.00502 g 
BSA 1 0.00500 g 
Disk 2 0.00634g 
BSA 2 0.00504g 
Disk 3 0.00673 g 
BSA 3 0.00396 g 
Disk 4 0.006.79g 
BSA 4 0.00253 g 
Top Disk 5 0.00659 g 
Each of the BSA layers was evenly dispersed upon the 
polymer disk below it using a spatula. The RTV rubber was 
then applied as needed. The multilaminate systems that we 
created were visibly much bulkier than we would prefer; the 
difficulty of applying such a course material as RTV rubber 
makes the tablet appear messy and mechanically rigid. Swell 
ing Studies and Release Studies. Studies were done on the 
Swelling and release of these multilaminate systems. These 
studies show the release of bovine serum albumin from glu 
cose-recognitive planar multilayered systems. FIG. 10 shows 
the behavior of such systems in a 100 mg/dL solution of 
glucose. Clearly, all incorporated BSA was released in two 
pulses. The recognitive layers correspond to regions AB and 
CD while the releasing layers correspond to regions BC and 
DE. 
It is contemplated that any embodiment discussed in this 
specification can be implemented with respect to any method, 
kit, reagent, or composition of the invention, and vice versa. 
Furthermore, compositions of the invention can be used to 
achieve methods of the invention. 
It will be understood that particular embodiments 
described herein are shown by way of illustration and not as 
limitations of the invention. The principal features of this 
invention can be employed in various embodiments without 
departing from the scope of the invention. Those skilled in the 
art will recognize, or be able to ascertain using no more than 
US 8,771,713 B2 
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routine experimentation, numerous equivalents to the specific 
procedures described herein. Such equivalents are considered 
to be within the scope of this invention and are covered by the 
claims. 
All publications and patent applications mentioned in the 
specification are indicative of the level of skill of those skilled 
in the art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli 
cation was specifically and individually indicated to be incor 
porated by reference. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
meaning of “one or more.” “at least one.” and “one or more 
than one.” The use of the term 'or' in the claims is used to 
mean “and/or unless explicitly indicated to refer to alterna 
tives only or the alternatives are mutually exclusive, although 
the disclosure supports a definition that refers to only alter 
natives and “and/or.” Throughout this application, the term 
“about is used to indicate that a value includes the inherent 
variation of error for the device, the method being employed 
to determine the value, or the variation that exists among the 
study Subjects. 
As used in this specification and claim(s), the words "com 
prising (and any form of comprising. Such as “comprise' and 
“comprises”), “having (and any form of having, such as 
“have” and “has'), “including (and any form of including, 
such as “includes and “include’) or “containing (and any 
form of containing, such as “contains' and "contain’) are 
inclusive or open-ended and do not exclude additional, unre 
cited elements or method steps. 
The term “or combinations thereofas used herein refers to 
all permutations and combinations of the listed items preced 
ing the term. For example, A, B, C, or combinations thereof 
is intended to include at least one of A, B, C, AB, AC, BC, or 
ABC, and if order is important in a particular context, also 
BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing 
with this example, expressly included are combinations that 
contain repeats of one or more item or term, such as BB, 
AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and 
so forth. The skilled artisan will understand that typically 
there is no limit on the number of items or terms in any 
combination, unless otherwise apparent from the context. 
All of the compositions and/or methods disclosed and 
claimed herein can be made and executed without undue 
studyation in light of the present disclosure. While the com 
positions and methods of this invention have been described 
in terms of preferred embodiments, it will be apparent to 
those of skill in the art that variations may be applied to the 
compositions and/or methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
All Such similar substitutes and modifications apparent to 
those skilled in the art are deemed to be within the spirit, 
Scope and concept of the invention as defined by the appended 
claims. 
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What is claimed is: 
1. A composition comprising: 
a multi-bilayer polymer tablet comprising 
a first bilayer comprising at least one first molecular 
imprinted recognition polymeric first layer comprising 
an imprint that recognizes a template molecule and at 
least one first active agent in a second layer, wherein the 
at least one molecular imprinted recognition polymeric 
first layer recognizes a first template molecule to release 
the at least one first active agent; 
at least a second bilayer in communication with the first 
bilayer wherein each second bilayer comprises at least 
one second molecular imprinted recognition polymeric 
layer and at least one second active agent in a second 
layer; and wherein the at least one second molecular 
imprinted recognition polymeric layer recognizes a sec 
ond template molecule to release the at least one second 
active agent, wherein the first bilayer and the at least a 
second bilayer are compressed into a single tablet, 
wherein the at least one first molecular imprinted recogni 
tion polymeric layer and the at least one second molecu 
lar imprinted recognition polymeric layer are (poly) 
methacrylic acid molecular imprinted recognition 
polymers; 
wherein the at least one first active agent and the at least one 
second active agent are insulin; and 
wherein the first template molecule and the second tem 
plate molecule are glucose. 
2. The composition of claim 1, wherein 
the at least one second molecular imprinted recognition 
polymeric layer, 
the at least one molecular imprinted recognition polymeric 
first layer or both further comprises microparticles. 
3. The composition of claim 1, wherein the first bilayer, the 
at least a second bilayer or both further comprise at least one 
of an adhesive, a binder, an inactive matrix or an excipient. 
4. The composition of claim 1, wherein the at least one 
second molecular imprinted recognition polymeric layer, the 
at least one first molecular imprinted recognition polymeric 
layer or both is at least one of biocompatible, biodegradable, 
swellable, water-soluble, or porous. 
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5. The composition of claim 1, wherein the recognitive 
portion of the bilayer unit is disrupted due to: osmosis upon 
the presence and binding of the molecule leading to rupture 
due to swelling; change of the solubility of the polymeric 
network leading to polymer dissolution; local temperature 
changes leading to expansion of the polymeric network and 
combinations thereof. 
6. The composition of claim 1, further comprising a third 
layer in communication with the first bilayer, the at least a 
Second bilayer, or both to form a tri-layer and an active agent 
is loaded into the third layer. 
7. The composition of claim 1, wherein the composition 
comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 
19 or 20 layers. 
8. The composition of claim 1, wherein the at least one first 
active agent, the at least one second active agent or both are 
pharmaceuticals. 
9. The composition of claim 1, wherein the multi-bilayer 
polymer tablet further comprises a coating. 
10. The composition of claim 1, wherein the multi-bilayer 
polymer tablet is a sphere, film, planar, semi-spherical, cyl 
inder, rod, hemispheres, conical, hemi-cylinders, bi-layer and 
combination thereof. 
11. A composition comprising: 
a bilayer polymer tablet comprising at least 2 bilayers 
wherein each of the at least 2 bilayers comprise: 
a first molecular imprinted recognition layer comprising a 
molecular imprinted recognition polymer comprising 
poly methacrylic acid comprising an imprint that recog 
nizes a template molecule and 
a second active agent layer in contact with the first molecu 
lar imprinted recognition layer comprising an active 
agent wherein the molecular imprinted recognition 
polymer recognizes a template molecule and exposes 






wherein the first molecular recognition and second 
active agent layers are compressed into a single tablet 
wherein the active agent is insulin; and the template 
molecule is glucose. 
12. The composition of claim 11, wherein the molecular 
imprinted recognition polymer further comprises micropar 
ticles. 
13. The composition of claim 11, further comprising at 
least one of an adhesive, a binder, an inactive matrix or an 
excipient in the first molecular imprinted recognition layer, 
the second active agent layer or both. 
14. The composition of claim 11, wherein the molecular 
imprinted recognition polymer is at least one of biocompat 
ible, biodegradable, swellable, water-soluble, or porous. 
15. The composition of claim 11, wherein the recognitive 
portion of the bilayer polymer tablet is disrupted due to: 
osmosis upon the presence and binding of the molecule lead 
ing to rupture due to swelling: change of the solubility of the 
polymeric network leading to polymer dissolution; local tem 
perature changes leading to expansion of the polymeric net 
work and combinations thereof. 
16. The composition of claim 11, wherein the active agent 
is loaded into two or more layers. 
17. The composition of claim 11, wherein active agent is 
selected from pharmaceuticals. 
18. The composition of claim 11, wherein the bilayer poly 
mer tablet further comprises a coating. 
19. The composition of claim 11, wherein the bilayer poly 
mer tablet is a sphere, film, planar, semi-spherical, cylinder, 
rod, hemispheres, conical, hemi-cylinders and combination 
thereof. 
20. The composition of claim 11, wherein the composition 
comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 
19 or 20 layers. 
